Cannabinoid Receptor Type 2 Stimulation Treats COVID-19

지난달

CBR2_Covid-19.png

Agonists of the cannabinoid type 2 receptor (CBR2), like ∆9THC, the novel ∆9-THCP, and the synthetic HU910, HU308 and JWH133, bind to the CBR2 to treat COVID-19 through immunopsuppression and reduction of pro-inflammatory cytokines. Cannabidiol (CBD) also exerts anti-inflammatory and immunosuppressive effects independently of the CBR2, by increasing anandamide levels.

CBR2_COVI19-2.png

Proper stimulation of their CB2 receptor, could be proposed to improve COVID-19 patients’ conditions with a double function: to repair tissue damages on stem cells and to drive immune response in a protective direction immunomodulating cells.

Source:


Rossi, F., Tortora, C., Argenziano, M., Di Paola, A., & Punzo, F. (2020). Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?. International journal of molecular sciences, 21(11), E3809. Full study available for download.

Authors get paid when people like you upvote their post.
If you enjoyed what you read here, create your account today and start earning FREE STEEM!
STEEMKR.COM IS SPONSORED BY
ADVERTISEMENT
Sort Order:  trending

This post has been rewarded by the Steem Community Curation Project. #communitycuration06
RESPECT
#SteemOn